Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 23 results found. Search for [ Baricitinib ]

Results 1 to 21 of 23
BusinessToday.In
June 1, 2021
Lilly is engaging in dialogue with government and regulatory authorities to donate bamlanivimab and etesevimab to speed up access and provide treatment options for patients with COVID-19, says the company


BusinessToday.In
May 24, 2021
Presently six firms - BDR Pharma, Bharat Serums and Vaccines, Mylan, Sun Pharma, Cipla, and Life Care - are producing  Amphotericin B


BusinessToday.In
May 19, 2021
For the fiscal year 2021, net profit stood at Rs 1,252 crore as compared to Rs 1,052 crore in FY20. Revenue from operations grew 0.8 per cent to Rs 8,005 crore from Rs 7,939 crore in the previous year


BusinessToday.In
May 17, 2021
Stocks in news: Bharti Airtel, Mphasis, Cipla, Hero MotoCorp, Punjab National Bank, Adani Green Energy and more


Reuters
May 15, 2021
Backorders and complaints over low supply started moderating in the second week of May, the drugmaker said, after it began ramping up production of the antiviral drug last month


BusinessToday.In
May 13, 2021
Baricitinib has received 'restricted emergency use approval' from the health ministry's central drugs standard control organisation for use in combination with Remdesivir for treatment of suspected or confirmed COVID-19 patients


BusinessToday.In
May 13, 2021
Production of all drugs, including Remdesivir, has been ramped up significantly in last few weeks. Officials informed PM the supply of oxygen is now more than 3 times supply during peak of first wave. He also reviewed status of procurement of oxygen concentrators, oxygen cylinders, and PSA plants


Rai Vinaykumar
May 12, 2021
Vaccine wastage happens in all vaccination programmes across the world and is unavoidable. However, with proper planning and care, the wastage can be reduced.


Joe C Mathew
May 12, 2021
India is sourcing almost 70 per cent of drug intermediates, key starting materials and active pharmaceutical ingredients (APIs) -- all essential raw materials needed to manufacture medicines from China


BusinessToday.In
May 12, 2021
According to a new tracker developed by researchers at the Cambridge Judge Business School and the National Institute of Economic and Social Research, new cases have peaked in the country


BusinessToday.In
May 12, 2021
Dr Reddy's has also tied up with Russian Direct Investment Fund, Russia's sovereign wealth fund that has bankrolled Sputnik V. It has also collaborated with DRDO to develop an anti-Covid drug, 2-deoxy-D-glucose (2-DG), which has also received approval from DCGI


BusinessToday.In
May 12, 2021
Stocks in news: RIL, JM Financial, Godrej Consumer, Asian Paints and more


BusinessToday.In
May 11, 2021
The pharma stock, which forms part of ace investor Rakesh Jhunhjhunwala's portfolio, has gained 40.97 per cent in one year and risen 23 per cent since the beginning of this year


BusinessToday.In
May 11, 2021
The three Indian drugmakers - Cipla Ltd, Lupin Ltd, and Sun Pharma will collaborate with Lilly to manufacture and distribute Baricitinib in India. The drug is approved by the Central Drugs Standard Control Organization (CDSCO) for restricted emergency use in India


Joe C Mathew
May 10, 2021
Lilly said the company is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses. These voluntary licensing agreements will ensure high quality manufacturing and accessibility of Baricitinib


BusinessToday.In
May 10, 2021
Baricitinib was issued a restricted emergency use approval by the health ministry's CDSCO for the use in combination with Remdesivir for treatment of Covid-19


BusinessToday.In
May 6, 2021
The approval was granted by the Central Drugs Standards Control Organisation (CDSCO) basis data filed with the US regulators as well as the scientific opinion of an European regulatory panel


BusinessToday.In
May 4, 2021
Bajaj Healthcare Limited (BHL) has received approval from India's drug regulator, to manufacture and market 'Favijaj' in India for the treatment of COVID-19 from May 4, 2021, onwards


PB Jayakumar
May 3, 2021
Demand fell to almost nil by January after the first wave of the pandemic in the country. Since there was no demand, most manufacturers stopped giving fresh orders for manufacturing


PTI
May 3, 2021
Petitioner Dincur Bajaj said since the export of Remdesivir has been banned by the Centre, the companies which were producing it for export be permitted to manufacture and sell it in the domestic market


PAGES 1 OF 2  12